The cutting-edge technology used in COVID-19 shots may lead to new treatments for other diseases. But some conservatives are ...

Let’s talk about measles. Not compelling? Not convinced? Go to news.google.com and search for “measles.” You’ll get news reports about infections that official data shows are coming at a faster clip ...

Researchers developed pig retinal organoids similar to human ones, advancing stem cell-based vision restoration and enabling ...

Nature's Toolbox (NTx), a life sciences company developing next-generation platforms for RNA and protein manufacturing, today announced the founding of its Scientific Advisory Board (SAB) with ...

Dyne Therapeutics’ DYNE-101 shows positive results in phase 1/2 ACHIEVE study. Read why DYN stock may rise with FDA approval and a $2.78B market opportunity.

ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer and Shionogi as shareholders, today announced positive findings from the company’s EMBRACE phase IIb study.

University at Albany researchers at the RNA Institute are pioneering new methods for designing and assembling DNA ...

Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) and Ono Pharmaceutical Co., Ltd (Ono), today announced that the two companies have ...

Researchers at the RNA Institute at the University at Albany are pioneering new methods for designing and assembling DNA ...

Arrowhead's ARO-C3 cut C3 levels by up to 89% and proteinuria by 41% in a Phase 1/2 trial. Additional results will be ...

Drug developers' dreams of silencing RNA as a way to step in front of a range of diseases have not lived up to early-day hype ...

They are based on RNA technology that dates back to the 1960s. Not all COVID-19 vaccines are mRNA vaccines. Novavax has a ...